Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECC 2015 | Changing the standard of care in previously treated metastatic renal cell carcinoma

Laurence Albiges • 25 Sep 2015
ECC 2015
Genitourinary Cancer Cabozantinib Everolimus Nivolumab

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, from Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.

More from Laurence Albiges

2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
4:21
Biomarker development in RCC and UC
Laurence Albiges • 23 Sep 2021
2:24
Current and emerging treatment strategies for patients with mccRCC
Laurence Albiges • 23 Sep 2021
1:50
BIONIKK: the first trial study in mccRCC
Laurence Albiges • 18 Sep 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals